|
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors Clinical research trials and Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors. Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors clinical trial. Human subjects often receive the most effective healthcare possible for their Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors  Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
For Condition: Ovarian Neoplasms,Prostatic Neoplasms,Lung Neoplasms,Breast Neoplasms
Status: Recruiting
Sponsor(s): Pharmacyclics ,
Synopsis: The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - 18 years old - Histologically or cytologically confirmed diagnosis of cancer (i.e., Unresectable locally advanced or metastatic non-small-cell lung carcinoma (NSCLC) that had progressed during or after one or more chemotherapy regimens; Metastatic breast cancer; Hormone-refractory prostate cancer; Recurrent or refractory ovarian cancer; Sarcoma) - ECOG performance status score either 0 or 1 - Willing and able to provide written informed consent Exclusion Criteria: Laboratory Values of: - Absolute neutrophil count < 2000/µL - Platelet count < 100,00/µL - AST or ALT > 1.5 x the upper limit of normal - Alkaline phosphatase > 5 x the upper limit of normal - Bilirubin > ULN - Creatinine > 2.0 mg/dL and - Peripheral neuropathy NCI CTC Grade 3 or higher - Chemotherapy, radiation therapy, immunotherapy, or systemic biologic - anticancer therapy within 21 days before beginning study treatment - Known history of brain metastases or spinal cord compression - Uncontrolled hypertension - Myocardial infarction within 6 months before beginning study treatment - Unstable angina pectoris, uncontrolled congestive heart failure, or uncontrolled serious arrhythmias - Known sensitivity to or intolerable adverse effects from taxanes or polysorbate 80 - Known history of porphyria (testing not required at screening) - Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening) - Known history of HIV infection (testing not required at screening) - Female who is pregnant or lactating (pregnancy test is required for all female patients of childbearing potential) - Female of childbearing potential or sexually active male unwilling to use adequate contraceptive protection - Physical or mental condition that makes patient unable to complete specified follow-up assessments
Total Enrollment: 20
Location and Contact Information:
University of Rochester Cancer Center *Recruiting*
Rochester, New York,
United States
Recruiting
Additional Information:
Study ID Numbers: PCYC-0214;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00080041
Other Prostatic Neoplasms Studies:
1. Safety and Efficacy of Atrasentan in Men with Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
2. Ketoconazole Plus Docetaxel to Treat Prostate Cancer
3. Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
4. Sequential Vaccinations in Prostate Cancer Patients
5. Study of a 6-Month Sustained-release Formulation of Leuprolide in Prostate Cancer
Related Studies:
Other Prostatic Neoplasms Clinical Trials
Other New York Clinical Trials
Other Rochester Clinical Trials
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
|
|
|
|
|
|
|
|
